On the basis of the available research progress, we propose that in the malignant progression of HER2 + IBC tumour cells, the IBC-specific inflammatory environment promotes the active degree of histone acetylation in tumour cells, which in turn mediates the EMT transformation of IBC tumour cells and promotes invasion and metastasis; therefore, targeting the inflammation–histone acetylation–EMT signalling axis is necessary for IBC tumour therapeutic exploration. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.